Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1993 Jan;36(1):9–17. doi: 10.1007/BF01789125

Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: Effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene

Lei Ding 1, El-Nasir Lalani 2, Mark Reddish 3, Rao Koganty 3, Ting Wong 3, John Samuel 1, Mary Beth Yacyshyn 4, Alison Meikle 4, Peter Y S Fung 5, Joyce Taylor-Papadimitriou 2, B Michael Longenecker 1,3,4,✉
PMCID: PMC11039006  PMID: 8422670

Abstract

The immune response of CAF1 mice to various synthetic peptides (SP) related to the amino acid sequence (PDTRPAPGSTAPPAHGVTSA) of the tandem repeat of the MUC1 human breast mucin core peptide was evaluated. The most immunogenic preparations of the synthetic peptides were those conjugated to keyhole limpet hemocyanin (KLH) or clustered in a dendritic multiple antigenic peptide (MAP-4) configuration. The mice were immunized subcutaneously with synthetic peptides emulsified in RIBI adjuvant, employing various immunization protocols. Equivalently high IgG responses were induced using SP-KLH conjugates (GVTSAPDTRPAPGSTA-KLH) or an SP — MAP-4 chimeric configuration (SP1-6), which also included a universal malarial CST-3 T-helper epitope (SP1-6 = SAPDTRPAEKKIAKMEKASSVFNVVNS — MAP-4). These IgG antibodies bound both the appropriate MUC1 synthetic peptides and the cell surface expressed MUC1 mucin on murine mammary cells that had been transfected with the human MUC1 gene and a human breast cancer cell line that expresses cell-surface MUC1. A MAP-4 molecule, which included the entire 20-aminoacid sequence of the MUC1 tandem repeat (SP1-5 = PDTRPAPGSTAPPAHGVTSA—MAP-4) induced a poor IgG response. In contrast, all three types of molecule: SP-KLH, SP1-6 and SP1-5, were found to be good immunogens for the induction of specific delayedtype hypersensitivity (DTH) reactions measured using either synthetic peptides or MUC1-transfected cells. In addition, immunization with irradiated MUC1-transfected cells induced strong DTH reactions measured using synthetic peptides that expressed the PDTRP sequence, which has been shown to be, or to overlap, a T cell epitope in humans and a B cell epitope in mice. Finally, it was demonstrated that synthetic MUC1 peptide “vaccines” could be used both prophylactically and therapeutically to inhibit the growth of MUC1-transfected tumor cells and prolong the survival of tumor-bearing mice.

Key words: Cancer peptide immunogens, Active specific immunotherapy

References

  • 1.Barnd DL, Lan MS, Metzgar RS, Finn OJ. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA. 1989;86:7159. doi: 10.1073/pnas.86.18.7159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Burchell J, Gendler S, Taylor-Papadimitriou J, Girling A, Lewis A, Millis R, Lamport D. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res. 1987;47:5476. [PubMed] [Google Scholar]
  • 3.Codington JF, Frim DM. Cell-surface macromolecular and morphological changes related to allotransplantability in the TA3 tumor. In: Manson LA, editor. Biomembranes, vol 2. New York: Plenum; 1983. p. 207. [PubMed] [Google Scholar]
  • 4.Codington JF, Bhavanandan VP, Bloch KJ, Nikrui N, Ellard JV, Wang PS, Jeanloz RW. Antibody to epiglycanin and radioimmunoassay to detect epiglycanin-related glycoproteins in body fluids of cancer patients. JNCI. 1984;73:1029. [PubMed] [Google Scholar]
  • 5.Fung PS, Longenecker BM. Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-Ha) Cancer Res. 1991;51:1170. [PubMed] [Google Scholar]
  • 6.Fung PYS, Madej M, Koganty R, Longenecker BM. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res. 1990;50:4308. [PubMed] [Google Scholar]
  • 7.Friberg S., Jr Comparison of an immunoresistant and an immunosusceptible ascites subline from murine tumor TA3: I. Transplantability, morphology and some physicochemical characteristics. JNCI. 1972;48:1463. [PubMed] [Google Scholar]
  • 8.Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. Biol Chem. 1988;263:12 820. [PubMed] [Google Scholar]
  • 9.Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J, Pemberton L, Lalani E-N, Wilson D. Molecular cloning and expression of the human tumor-associated polymorphic epithelial mucin, PEM. Biol Chem. 1990;265:15 286. [PubMed] [Google Scholar]
  • 10.Hanisch F, Uhlenbruck G, Egge H, Peter-Katalinic J. A B72.3 second-generation-monoclonal antibody (CC49) defines the mucincarried carbohydrate epitope Galβ(1–3)(NeuAcα(2–6))GalNAc. Biol Chem Hoppe-Seyler. 1989;370:21. doi: 10.1515/bchm3.1989.370.1.21. [DOI] [PubMed] [Google Scholar]
  • 11.Hareuveni M, Gautier C, Kieny M-P, Wreschner D, Chambon P, Lathe R. Vaccination against tumor cells expressing breast cancer epithelial tumor antigen. Proc Natl Acad Sci USA. 1990;87:9498. doi: 10.1073/pnas.87.23.9498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Henningson CM, Selvaray S, MacLean GD, Suresh MR, Noujaim AA, Longenecker BM. T cell recognition of tumorassociated glycoprotein and its synthetic carbohydrate epitopes: stimulation of anticancer T cell immunity in vivo. Cancer Immunol Immunother. 1987;25:231. doi: 10.1007/BF00199152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Ho PC, Muteh DA, Winkel KD, Saul AJ, Jones GL, Doran TJ, Rzepczyk CM. Identification of two promiscuous T-cell epitopes from tetanus toxin. Eur J Immunol. 1990;20:477. doi: 10.1002/eji.1830200304. [DOI] [PubMed] [Google Scholar]
  • 14.Hull SR, Bright A, Carraway KL, Abe M, Hayes DF, Kufe D. Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line. Cancer Commun. 1989;1:261. [PubMed] [Google Scholar]
  • 15.Itzkowitz SH, Bloom EJ, Kokal WA, Modin G, Hakomori S-I, Kim YS. Sialosyl-Tn: a novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer. 1990;66:1960. doi: 10.1002/1097-0142(19901101)66:9<1960::aid-cncr2820660919>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  • 16.Jentoff N. Why are proteinsO-glycosylated? Trends Biochem Sci. 1990;15:291. doi: 10.1016/0968-0004(90)90014-3. [DOI] [PubMed] [Google Scholar]
  • 17.Jerome KR, Barnd DL, Bendt KM, Boyer CM, Taylor-Papadimitriou J, McKenzie IFC, Bast RC, Jr, Finn OJ. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the malignant cells. Cancer Res. 1991;51:2908. [PubMed] [Google Scholar]
  • 18.Kahn M, Sugawara H, McGowan P, Okuno K, Nagoya S, Hellström KE, Hellström I, Greenberg P. CD4+ cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen. J Immunol. 1991;146:3235. [PubMed] [Google Scholar]
  • 19.Kurosaka A, Kitagawa H, Fukui S, Numata Y, Nakada H, Funakoshi I, Kawasaki T, Ogawa T, Iijima H, Yamashina I. A monoclonal antibody that recognizes a cluster of a disaccharide, NeuAcα2-6GalNAc, in mucin-type glycoproteins. J Biol Chem. 1988;263:8724. [PubMed] [Google Scholar]
  • 20.Lalani E-N, Berdichevsky F, Boshell M, Shearer M, Wilson D, Stauss H, Gendler SJ, Taylor-Papadimitriou J. Expression of the gene coding for a human mucin in mouse mammary tumour cells can affect their tumorigenicity. J Biol Chem. 1991;266:15 420. [PubMed] [Google Scholar]
  • 21.Lan MS, Batra SK, Qi W-N, Metzgar RS, Hollingsworth MA. Cloning and sequencing of a human pancreatic tumor mucin cDNA. J Biol Chem. 1990;265:15 294. [PubMed] [Google Scholar]
  • 22.Layton GT, Devine PL, Warren JA, Birrell G, Xing P-X, Ward BG, McKenzie IFC. Monoclonal antibodies reactive with the breast carcinoma-associated mucin core protein repeat sequence peptide also recognize the ovarian carcinoma-associated sebaceous gland antigen. Tumor Biol. 1990;11:274. doi: 10.1159/000217661. [DOI] [PubMed] [Google Scholar]
  • 23.MacLean G, Longenecker BM (1991) Novel synthetic immunother-apeutic vaccines for cancer: induction of hapten specific humoral immunity with reactivity with tumor cells. In: SBI '91 Biological Therapy of Cancer-VI Program and Abstracts. Society for Biological Therapy 1991 Annual Meeting, Pittsburgh, Pennsylvania
  • 24.MacLean GD, Bowen-Yacyshyn MB, Samuel J, Meikle A, Stuart G, Nation J, Poppema S, Jerry M, Koganty R, Wong T, Longenecker BM. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. J Immunother. 1992;11:292. doi: 10.1097/00002371-199205000-00008. [DOI] [PubMed] [Google Scholar]
  • 25.Miller SC, Hay ED, Codington JF. Ultrastructural and histochemical differences in cell surface properties of strain-specific and non-strain specific TA3 adenocarcinoma cells. J Cell Biol. 1977;72:511. doi: 10.1083/jcb.72.3.511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Parry G, Beck JC, Moss L, Bartley J, Ojakian GK. Determination of apical membrane polarity in mammary epithelial cell cultures. The role of cell-cell, cell-substrate and membrane-cytoskeletal interaction. Exp Cell Res. 1990;188:302. doi: 10.1016/0014-4827(90)90174-9. [DOI] [PubMed] [Google Scholar]
  • 27.Peat N, Gendler SJ, Lalani E-N, Duhig T, Taylor-Papadimitriou J. Tissue specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice. Cancer Res. 1992;52:1954. [PubMed] [Google Scholar]
  • 28.Samuel J, Noujaim AA, MacLean GD, Suresh MR, Longenecker BM. Analysis of human tumor-associated Thomsen-Friedenreich antigen. Cancer Res. 1990;50:4801. [PubMed] [Google Scholar]
  • 29.Singhal A, Fohn M, Hakomori S. Induction of α-N-acetylgalactosamine-O-serine/threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice. Cancer Res. 1991;51:1406. [PubMed] [Google Scholar]
  • 30.Sinigaglia F, Guttinger M, Kilgus J, Doran DM, Martile H, Etlinger H, Trzeciak A, Gillessen D, Pink JRL. A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature. 1988;336:778. doi: 10.1038/336778a0. [DOI] [PubMed] [Google Scholar]
  • 31.Springer GF. T and Tn, general carcinoma autoantigens. Science. 1984;224:1198. doi: 10.1126/science.6729450. [DOI] [PubMed] [Google Scholar]
  • 32.Taylor-Papdimitriou J, Gendler SJ. Molecular aspects of mucins. In: Hilgers J, Zotter S, editors. Cancer reviews. vol. 11–12. Copenhagen, Denmark: Munksgaard; 1988. p. 11. [Google Scholar]
  • 33.Torben F, Orntoft NH, Langkilde NC. O-Linked mucin-type glycoproteins in normal and malignant colon mucosa: lack of T-antigen expression and accumulation of Tn and sialosyl-Tn antigens in carcinomas. Int J Cancer. 1990;45:666. doi: 10.1002/ijc.2910450416. [DOI] [PubMed] [Google Scholar]
  • 34.Wong RCK, Remold-O'Donnell E, Vercelli D, Saneho J, Terhorst C, Rosen F, Geha R, Chatila T. Signal transduction via leukocyte antigen CD43 (sialophorin). Feedback regulation by protein kinase C. J Immunol. 1990;144:1455. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES